This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Health Canada Issued an NPN to Advitech for Dermylex

Advitech Inc. | Mar 10, 2010

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today that the Natural Health Products Directorate (NHPD) has issued to Advitech, on March 8, 2010, a Natural Product Number (NPN) for one of its main products, XP-828L/Dermylex. The issuance of a product licence for XP-828L/Dermylex means that the product has been assessed by Health Canada and has been found to be safe, effective and of high quality under its recommended conditions of use.

As a result, for XP-828L/Dermylex, the approved claim authorized by the NHPD to appear on the product label is: "Clinically proven. Helps improve the symptoms of psoriasis".

"The issuance of this NPN is significant for Advitech as it will allow the Corporation to distribute XP-828L/Dermylex in Canada and in many other countries in which a NPN is mandatory for the registration of a Canadian Natural Health Product" stated Michael Stangel, President and Chief Executive Officer of Advitech. He added "This will allow us to finalize the registration of XP-828L/Dermylex in many countries where our status was pending upon obtaining the NPN and allow us to generate additional sales related to this issuance in the upcoming months. To our knowledge, XP-828L is the only natural health product that has been proven to help psoriasis patients and for which a NPN has been granted."

Advitech first applied for a Product Licence Application for XP-828L in December 2007. XP-828L is marketed as Dermylex in Canada.